1. Prognosis and mortality of hypertrophic obstructive cardiomyopathy;Hardarson, T.; de la Calzada, C.S.; Curiel, R.; Goodwin, J.F.;Lancet,1973
2. Sudden death in patients with effects were not, however, seen with this drug; seven hypertrophic cardiomyopathy: characterization of 26 of eight patients continued to have ventricular patients without functional limitation;Maron, B.J.; Roberts, W.C.; Edwards, J.E.; HA, Jr, McAllister; Foley, D.D.; Epstein, S.E.;Am J Cardiol tachycardia and,1978
3. Although clinical studies suggest attenuation of the electrocardiographic9 and echocardiographic8 features of ventricular hypertrophy on verapamil, the natural history of ventricular hypertrophy in hypertrophic cardiomyopathy is variable and the relation of hyper- Oakley CM, Goodwin JF. Prognosis in hypertrophic cardiomyopathy;McKenna, W.J.; Deanfield, J.E.; Faruqui, A.M.A.; England, D.,1981
4. Prevalence of arrhythmias during 24 hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic trophy to sudden death is problematic. Of the cardiomyopathy;Savage, D.D.; Seides, S.F.; Maron, B.J.; Myers, D.J.; Epstein, S.E.;Circulation,1979
5. Reduction of septal thickness following verapamil in patients with asymmetric septal hypertrophy (ASH) (abstract);Troesch, M.; Hirzel, H.O.; Jenni, R.; Krayenbuhl, H.P.;Circulation,1979